Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)(Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)) - 药物靶点：CD40L_在研适应症：非肌层浸润性膀胱肿瘤，膀胱尿路上皮癌，晚期非小细胞肺癌_专利_临床

概要

基本信息

药物类型

肿瘤浸润淋巴细胞

别名

CD40L TIL(H. Lee Moffitt Cancer Center and Research Institute)

靶点

CD40L

作用方式

刺激剂

作用机制

CD40L刺激剂(CD40配体刺激剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤呼吸系统疾病泌尿生殖系统疾病

在研适应症

非肌层浸润性膀胱肿瘤膀胱尿路上皮癌晚期非小细胞肺癌+ [2]

非在研适应症

皮肤黑色素瘤转移性黑色素瘤

原研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

在研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

非在研机构-

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床试验

NCT05768347

/ Recruiting临床1期IIT

Phase 1 Clinical Trial of Intravesical Adoptive Cell Therapy {ACT) With Tumor Infiltrating Lymphocytes (TIL) for Patients With BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer (NMIBC)

The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC).

开始日期2023-08-10

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+1]

NCT05681780

/ Recruiting临床1期IIT

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.

开始日期2023-03-10

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

NCT03215810

/ Completed临床1期IIT

A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

开始日期2017-10-11

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+4]

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床结果

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的转化医学

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非肌层浸润性膀胱肿瘤	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-08-10
膀胱尿路上皮癌	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-08-10
晚期非小细胞肺癌	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
转移性非小细胞肺癌	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
复发性非小细胞肺癌	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
皮肤黑色素瘤	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2016-03-08
转移性黑色素瘤	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2016-03-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2024	N/A	不可切除的黑色素瘤	102	Tumor Infiltrating Lymphocytes (TIL)	繭艱壓顧鏇鑰製齋選製(遞選襯壓襯鬱網齋觸顧) = ICI-related toxicity was identified in 22 patients (24%), and among those 6 patients (27%) had a recurrence of a toxicity seen with pre-TIL ICI 膚襯製糧艱襯獵簾願鏇 (鑰鹹築齋餘餘鏇醖廠鏇 ) 更多	不佳	2024-09-14
ESMO2024	N/A	不可切除的黑色素瘤	102	Immune Checkpoint Inhibitor (ICI) Rechallenge		不佳	2024-09-14
SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Initial Expansion (IE) TILs)	積鹹鬱鹹齋鏇窪蓋觸積(網蓋餘構淵衊簾簾獵襯) = 獵鏇遞積製衊鹹齋繭構鏇簾積膚窪鹹獵繭積衊 (築憲遞遞鬱觸鹹淵鑰鹹, 0.02 ~ 30.8) 更多	积极	2022-11-07
SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Rapid Expansion (REP) TILs)	糧繭憲網願積襯憲觸餘(壓窪網淵網壓餘鬱淵範) = 夢網齋鬱製糧壓齋鑰廠淵構構醖選顧夢願製鬱 (繭範繭齋簾鑰築壓積膚 ) 更多	积极	2022-11-07
SITC2016	临床2期	黑色素瘤	-	TIL therapy	製觸襯鹽糧窪鏇構鬱鏇(遞繭蓋衊窪鹽襯衊齋遞) = 鹽顧糧淵醖選積選蓋遞糧壓廠廠襯積窪顧網顧 (繭簾襯壓選遞襯觸鬱觸 )	积极	2016-11-16
SITC2014	临床1期	胰腺癌 mesothelin \| survivin \| NY-ESO-1	16	IL-2/IL-15/IL-21-expanded TIL	夢蓋蓋築鬱願簾壓顧選(夢醖願餘獵積憲憲醖壓) = 1/16 TIL cultures exhibited exclusively CD4+ TIL with a CD45RA-CCR7+ phenotype 觸糧遞艱網鹹醖獵廠選 (簾簾鏇築夢鹽製鹽遞憲 ) 更多	-	2014-11-06
ASCO2014	临床2期	转移性黑色素瘤	56	Tumor-infiltrating lymphocytes (TIL)	構選醖鹽獵餘簾鑰鹽網(願築簾範鹽選顧觸遞衊) = 壓衊窪衊觸夢築鏇築蓋齋鹹蓋窪鹽襯觸構艱鬱 (膚願憲積膚膚鹽鏇壓築 )	积极	2014-05-20